19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis : A Randomized Clinical Trial

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival. Fedratinib, a JAK2-selective inhibitor, previously demonstrated clinically beneficial activity in patients with MF in early-phase trials.

          Related collections

          Author and article information

          Journal
          JAMA Oncology
          JAMA Oncol
          American Medical Association (AMA)
          2374-2437
          August 01 2015
          August 01 2015
          : 1
          : 5
          : 643
          Affiliations
          [1 ]Department of Medicine, Mayo Clinic, Rochester, Minnesota
          [2 ]Guy’s and St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London, England
          [3 ]University of Texas MD Anderson Cancer Center, Houston
          [4 ]Hospital Clinic, IDIBAPS University of Barcelona, Barcelona, Spain
          [5 ]Division of Hematology-Oncology, Mayo Clinic, Scottsdale, Arizona
          [6 ]Centre for Haematology and Stem Cell Transplantation, Heartlands Hospital, Birmingham, England
          [7 ]Department of Haematology and Stem Cell Transplantation, St István and St László Hospital, Budapest, Hungary
          [8 ]Hematology-Oncology Unit, Bnai-Zion Medical Center, Haifa, Israel
          [9 ]Groupe Hospitalo-Universitaire Nimes, Nimes, France
          [10 ]Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
          [11 ]Beatson West of Scotland Cancer Centre, Gartnavel General Hospital, Glasgow, Scotland
          [12 ]Hematology Department, Klaipeda Seamen’s Hospital, Klaipeda, Lithuania
          [13 ]Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
          [14 ]Brasov Country Hospital, Brasov, Romania
          [15 ]University Hospital Ospedale di Circolo e Fondazione Macchi, Varese, Italy
          [16 ]Sanofi Oncology, Cambridge, Massachusetts
          Article
          10.1001/jamaoncol.2015.1590
          26181658
          91e8323a-4eae-49c4-abf1-1bfd58e519d3
          © 2015
          History

          Comments

          Comment on this article